CSIMarket
 


Fibrogen Inc   (FGEN)
Other Ticker:  
 
 

FGEN's Net Cash Flow Growth by Quarter and Year

Fibrogen Inc 's Net Cash Flow results by quarter and year




FGEN Net Cash Flow (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -0.26 -103.30 103.20
III Quarter September -31.67 -11.80 -78.83 307.71
II Quarter June -35.97 -18.14 -80.15 -4.71
I Quarter March 32.85 14.67 -244.89 37.01
FY   -34.79 -15.53 -507.17 443.21



FGEN Net Cash Flow third quarter 2023 Y/Y Growth Comment
Fibrogen Inc in the third quarter 2023 recorded net cash outflow of $ -31.67 millions.

According to the results reported in the third quarter 2023, Fibrogen Inc achieved the best Net Cash Flow growth in Major Pharmaceutical Preparations industry. While Fibrogen Inc ' s Net Cash Flow no change of % ranks overall at the positon no. in the third quarter 2023.




FGEN Net Cash Flow ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - 603.48 %
III Quarter September - - - -
II Quarter June - - - -
I Quarter March 123.93 % - - -
FY   - - - -

Financial Statements
Fibrogen Inc 's third quarter 2023 Net Cash Flow $ -31.67 millions FGEN's Income Statement
Fibrogen Inc 's third quarter 2022 Net Cash Flow $ -11.80 millions Quarterly FGEN's Income Statement
New: More FGEN's historic Net Cash Flow Growth >>


FGEN Net Cash Flow (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -66.46 %
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - 152.28 %
FY (Year on Year)   - - - -




Net Cash Flow third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Cash Flow Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Cash Flow third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Cash Flow Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Cash Flow by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Fibrogen Inc 's Q/Q Net Cash Flow Growth


Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


FGEN's III. Quarter Q/Q Net Cash Flow Comment
Even if Fibrogen Inc in the III. Quarter 2023 admitted net cash outflow of $ -31.67 millions, it should be mentioned, that those numbers show slight up side in contrast to the -35.97 millions in the second quarter.

Within Major Pharmaceutical Preparations industry Fibrogen Inc achieved highest sequential Net Cash Flow growth. While Fibrogen Inc 's Net Cash Flow growth quarter on quarter, overall rank is .


Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


FGEN's III. Quarter Q/Q Net Cash Flow Comment
Although Fibrogen Inc in the III. Quarter 2023 admitted net cash outflow of $ -31.67 millions, some analyst point out, that current results show slight up side relative to the -35.97 millions in the second quarter.

Within Major Pharmaceutical Preparations industry Fibrogen Inc achieved highest sequential Net Cash Flow growth. While Fibrogen Inc 's Net Cash Flow growth quarter on quarter, overall rank is .


Fibrogen Inc 's 12 Months Net Cash Flow Growth Year on Year


Net Cash Flow TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Net Cash Flow 12 Months Ending $ -35.05 $ -15.17 $ 2.65 $ -15.52 $ -118.57
Y / Y Net Cash Flow Growth (TTM) - - - - -
Year on Year Net Cash Flow Growth Overall Ranking # # # # #
Seqeuential Net Cash Flow Change (TTM) - - - - -
Seq. Net Cash Flow Growth (TTM) Overall Ranking # # # # #




Cumulative Net Cash Flow growth Comment


Fibrogen Inc achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. .

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Cash Flow growth Comment


Fibrogen Inc achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. .

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Cash Flow Growth
Major Pharmaceutical Preparations Industry Net Cash Flow Growth Trends and Statistics
Healthcare Sector Net Cash Flow Growth Statistics
Net Cash Flow Growth Trends for overall market
FGEN's Net Cash Flow Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Cash Flow Growth
Lowest Ranking Net Cash Flow Growth
Net Cash Flow Growth for FGEN's Competitors
Net Cash Flow Growth for Fibrogen Inc 's Suppliers
Net Cash Flow Growth for FGEN's Customers

You may also want to know
FGEN's Annual Growth Rates FGEN's Profitability Ratios FGEN's Asset Turnover Ratio FGEN's Dividend Growth
FGEN's Roe FGEN's Valuation Ratios FGEN's Financial Strength Ratios FGEN's Dividend Payout Ratio
FGEN's Roa FGEN's Inventory Turnover Ratio FGEN's Growth Rates FGEN's Dividend Comparisons



Companies with similar Net Cash Flow no change for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Net Cash Flow for the quarter ending Sep 30 2023
Mirati Therapeutics Inc 287.63%$ 287.630 millions
Envista Holdings Corporation279.96%$ 279.956 millions
Repligen Corp271.45%$ 271.446 millions
Iovance Biotherapeutics inc 266.44%$ 266.437 millions
Orasure Technologies Inc249.29%$ 249.293 millions
Teladoc Health Inc 228.82%$ 228.824 millions
Immunitybio inc 218.18%$ 218.182 millions
Axogen inc 205.37%$ 205.366 millions
Amarin Corp Plcuk202.58%$ 202.576 millions
Trevena inc 175.52%$ 175.523 millions
Ikena Oncology Inc 173.39%$ 173.390 millions
Neurocrine Biosciences Inc 173.01%$ 173.006 millions
Aquestive Therapeutics Inc 160.06%$ 160.063 millions
Actavia Life Sciences Inc 151.37%$ 151.374 millions
Cytokinetics Incorporated146.32%$ 146.316 millions
Avanos Medical Inc 140.95%$ 140.952 millions
Lantheus Holdings Inc 134.62%$ 134.620 millions
Skye Bioscience Inc 125.55%$ 125.554 millions
Viridian Therapeutics Inc 122.74%$ 122.742 millions
Durect Corp121.69%$ 121.694 millions
Regeneron Pharmaceuticals Inc 118.81%$ 118.815 millions
Ensign Group Inc105.70%$ 105.703 millions
Vertex Pharmaceuticals Inc103.68%$ 103.679 millions
Tenaya Therapeutics Inc 96.61%$ 96.613 millions
Ainos Inc 94.42%$ 94.423 millions
Merck and Co Inc 93.77%$ 93.775 millions
Henry Schein Inc 93.33%$ 93.333 millions
Insulet Corporation90.23%$ 90.226 millions
Benitec Biopharma Inc 87.53%$ 87.531 millions
Anika Therapeutics Inc 86.37%$ 86.373 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com